Inhibitors of the Hepatitis C Virus RNA-Dependent RNA Polymerase NS5B

Viruses

Megan H. Powdrill¹  Jean A. Bernatchez¹ 

[1] ¹McGill University, Department of Microbiology and Immunology, 3775 University Room D6, Montreal Quebec, H3A2B4, Canada ²McGill University, Department of Biochemistry, 3775 University Room D6, Montreal Quebec, H3A2B4, Canada

关键词: HCV NS5B polymerase inhibitors;    drug resistance;    viral fitness;    genetic barrier;   

DOI  :  10.3390/v2102169

来源: mdpi

【 摘 要 】

More than 20 years after the identification of the hepatitis C virus (HCV) as a novel human pathogen, the only approved treatment remains a combination of pegylated interferon-α and ribavirin. This rather non-specific therapy is associated with severe side effects and by far not everyone benefits from treatment. Recently, progress has been made in the development of specifically targeted antiviral therapy for HCV (STAT-C). A major target for such direct acting antivirals (DAAs) is the HCV RNA-dependent RNA polymerase or non-structural protein 5B (NS5B), which is essential for viral replication. This review will examine the current state of development of inhibitors targeting the polymerase and issues such as the emergence of antiviral resistance during treatment, as well as strategies to address this problem.

【 授权许可】

CC BY   
This is an open access article distributed under the Creative Commons Attribution License (CC BY) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.